Aardvark Therapeutics (AARD) Non Operating Investment Income (2024 - 2026)
Aardvark Therapeutics (AARD) reported Non Operating Investment Income of -$13000.0 for Q1 2026, up 13.33% on a YoY basis from -$11470.6 in Q1 2025, and up 31.58% sequentially from -$19000.0 in Q4 2025.
Aardvark Therapeutics (AARD) Non Operating Investment Income (2024 - 2026) Analysis & Trends
Aardvark Therapeutics (AARD) has 3 years of Non Operating Investment Income data on file, last reported at -$13000.0 in Q1 2026.
- For the quarter ending Q1 2026, Non Operating Investment Income rose 13.33% year-over-year to -$13000.0; the trailing twelve-month figure through Mar 2026 stood at -$3000.0 (up 97.54% YoY), and the FY2025 full-year result was -$5000.0, up 97.7% from the prior year.
- Non Operating Investment Income improved to -$13000.0 in Q1 2026, from -$19000.0 in the prior quarter.
- In the past five years, Non Operating Investment Income ranged from a high of $36000.0 in Q3 2025 to a low of -$110000.0 in Q1 2024.
- A 3-year average of -$26111.1 and a median of -$15000.0 in 2025 frame the typical range for Non Operating Investment Income.
- Peak annual rise in Non Operating Investment Income reached 139.56% in 2025, while the deepest fall reached 123.33% in 2025.
- Tracing AARD's Non Operating Investment Income over 3 years: stood at -$46000.0 in 2024, then soared by 58.7% to -$19000.0 in 2025, then soared by 31.58% to -$13000.0 in 2026.
- Business Quant data shows AARD's Non Operating Investment Income at -$13000.0 in Q1 2026, -$19000.0 in Q4 2025, and $36000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Operating Investment Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,042.03 Bn | 67,041.74 Bn | - | - |
| 2 | Nanobiotix | 1,908.00 Bn | 1,907.94 Bn | - | - |
| 3 | Akari Therapeutics | 959.56 Bn | 959.56 Bn | - | - |
| 4 | BeOne Medicines | 472.89 Bn | 468.10 Bn | 1.35 Bn | - |
| 5 | Vertex Pharmaceuticals | 122.12 Bn | 114.87 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 70.04 Bn | 61.29 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.68 Bn | 62.68 Bn | - | - |
| 8 | Argenx Se | 55.90 Bn | 50.72 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.47 Bn | 34.46 Bn | 959.66 Mn | - |
| 10 | Aardvark Therapeutics | 142.24 Mn | 22.28 Mn | - | -13,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -13,000.00 |
| Mar 31, 2026 | -13,000.00 |
| Dec 31, 2025 | -19,000.00 |
| Dec 31, 2025 | -19,000.00 |
| Sep 30, 2025 | 36,000.00 |
| Sep 30, 2025 | 36,000.00 |
| Jun 30, 2025 | -7,000.00 |
| Jun 30, 2025 | -7,000.00 |
| Mar 31, 2025 | -15,000.00 |
| Mar 31, 2025 | -15,000.00 |
| Dec 31, 2024 | -46,000.00 |
| Dec 31, 2024 | -46,000.00 |
| Sep 30, 2024 | -91,000.00 |
| Sep 30, 2024 | -91,000.00 |
| Jun 30, 2024 | 30,000.00 |
| Jun 30, 2024 | 30,000.00 |
| Mar 31, 2024 | -110,000.00 |
| Mar 31, 2024 | -110,000.00 |